Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
IT0004147952
Thu, 19.09.2024
Newron Pharmaceuticals S.p.A.
Newron presents H1 2024 results and provides business update
Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial [ … ]
Thu, 19.09.2024
Newron Pharmaceuticals S.p.A.
Newron presents H1 2024 results and provides business update
Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial [ … ]
Tue, 25.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia
Leading schizophrenia experts predict earlier use of evenamide would benefit patients with inadequate response
Evena [ … ]
Tue, 18.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant schizophrenia
The company will host a Live-Webcast of the event, beginning at 9:00 AM EDT (2 [ … ]
Wed, 05.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
New hope emerges for treatment-resistant schizophrenia: leading KOLs to reveal insights into the neurobiology of treatment for both poorly responding and treatment-resistant patients
Company to lay out the roadmap for US and EU registration for evenamide
Milan [ … ]
Mon, 13.05.2024
Newron Pharmaceuticals S.p.A.
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings
Benefit on efficacy measures increased over time, suggesting larger [ … ]
Tue, 30.04.2024
Newron Pharmaceuticals S.p.A.
Newron announces positive top-line results
from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizoph [ … ]
Mon, 08.04.2024
Newron Pharmaceuticals S.p.A.
Data from Newron’s study 014/015 and an
evenamide clinical development outlook presented at
the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year
Presentatio [ … ]
Tue, 19.03.2024
Newron Pharmaceuticals S.p.A.
Newron presents 2023 financial results and provides 2024 outlook
Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financ [ … ]
Fri, 15.03.2024
Newron Pharmaceuticals S.p.A.
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones
Amended agreement envisages [ … ]